Extended Data Fig. 2: Extended analysis of mutated genes in the SU2C-MARK cohort and comparison to external cohorts. | Nature Genetics

Extended Data Fig. 2: Extended analysis of mutated genes in the SU2C-MARK cohort and comparison to external cohorts.

From: Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Extended Data Fig. 2: Extended analysis of mutated genes in the SU2C-MARK cohort and comparison to external cohorts.The alternative text for this image may have been generated using AI.

(a) Significant drivers identified independently in the SU2C-MARK cohort (left) as compared to TCGA Lung Adenocarcinoma (LUAD; right upper) and TCGA Lung Squamous Cell Carcinoma (LUSC; right lower). Of note, the SU2C-MARK cohort includes a mixture of frequent drivers observed in LUAD and LUSC, consistent with it representing pan-NSCLC histologies. (b) Kaplan-Meier curves comparing checkpoint blockade treated ATM mutant patients and ATM wildtype patients in the Memorial Sloan Kettering Cancer Center (MSKCC) Impact cohort. ATM mutated patients demonstrated improved survival compared to unmutated patients (p = 0.03, logrank test).

Back to article page